Mosaic ImmunoEngineering, Inc. (CPMV)
OTCMKTS · Delayed Price · Currency is USD
0.5240
-0.0809 (-13.37%)
At close: Dec 5, 2025
Mosaic ImmunoEngineering Employees
As of December 31, 2024, Mosaic ImmunoEngineering had 8 total employees, including 3 full-time and 5 part-time employees. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$134,351
Market Cap
3.79M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | 0 | - |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 1 | 14.29% |
| Dec 31, 2021 | 7 | 0 | - |
| Dec 31, 2020 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Zomedica | 152 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
Mosaic ImmunoEngineering News
- 1 year ago - Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc. - Accesswire
- 2 years ago - Mosaic ImmunoEngineering Announces Issuance of U.S. Patent Covering Cancer Treatment with Its Lead Immuno-Oncology Candidate MIE-101 - Accesswire
- 3 years ago - UPDATE: Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology Platform - Accesswire
- 3 years ago - Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology Plat-form - Accesswire
- 3 years ago - Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University - Accesswire
- 4 years ago - Newly Published Data Further Support Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma - Accesswire
- 4 years ago - Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation - Accesswire
- 4 years ago - Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference - Accesswire